Anpac Bio-Medical Science Company, Ltd., is led by award-winning and internationally respected biomedical and nanotechnology ... scientists, research and medical professionals, engineering experts and physicists -- creating and launching break-through, leading edge, early cancer and other disease screening, detection, and diagnostic technology. Anpac Bio’s "Cancer Differentiation Analysis" (CDA) liquid biopsy technology incorporates proprietary, in-vivo (or non-invasive) screening and diagnostics devices that measure simple, “Blood Biopsies” -- assessing multiple microscopic parameters in whole blood samples, often identifying cancer pre-Stage One. Comprehensive research validity data from over 80,000 cases to date indicate Anpac’s CDA screening and diagnostics far exceed existing or competing disease screening technologies - revealing a consistent sensitivity and specificity rate range of 70%-95% for over 26 different types of cancer to date. And it does so without any harmful side effects in patients; generating far fewer “false positives”; and at a cost substantially lower than traditional testing (such as imaging). Anpac Bio-Medical is an international company promoting a corporate culture of creativity, teamwork, balance, and commitment to excellence, family, and social responsibility. For more information regarding Anpac Bio-Medical Science Company, please check: www.AnpacBio.com. read more